Long-term outcome of the REMAGUS 02 trial, a multicenter randomised phase II trial in locally advanced breast cancer patients treated with neoadjuvant chemotherapy with or without celecoxib or trastuzumab according to HER2 status

Auteurs

Sylvie Giacchetti, Anne-Sophie Hamy, Suzette Delaloge, Etienne Brain, Frédérique Berger, Brigitte Sigal-Zafrani, Marie-Christine Mathieu, Philippe Bertheau, Jean Marc Guinebretière, Mahasti Saghatchian, Florence Lerebours, chafouny mazouni, Olivier Tembo, Marc Espié, Fabien Reyal, Michel Marty, Bernard Asselain, Jean-Yves Pierga